Summary
The claim concerns the FDA approval date, which is not supported or mentioned in the provided prescribing-information excerpts; therefore label alignment cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
Tezspire (tezepelumab-ekko) received U.S. FDA approval on March 16, 2022.
The provided FDA-approved label excerpts do not include any information about the FDA approval date or approval timeline; the claim is therefore unsupported by the supplied label content.
Contradictions
Important Omissions
No label-relevant information is provided in the claim beyond the FDA approval date; other label elements (indications, dosing, contraindications, warnings/precautions, interactions, populations, adverse reactions) are not addressed.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claim is administrative (approval date) and does not directly make treatment, dosing, safety, or contraindication assertions based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Approval date is not supported by the provided prescribing-information excerpts.
Suggested Improvement
Evaluate and report claims that are supported by the provided label sections (e.g., indication, dosing regimen, contraindications, warnings/precautions, interactions, and populations). If an approval-date claim is required, cite the specific label/official document section that contains the date.